Navigation Links
Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement

BALTIMORE, June 30 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a patent infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. (CellzDirect) in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction.  Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California.  The complaint alleges that certain processes and methods performed by CellzDirect associated with its in vitro drug testing services and its pooled cryopreserved hepatocyte products infringe one or more claims of U.S. Patent No. 7,604,929 (the '929 patent).  The complaint also alleges that Invitrogen is selling these infringing products and services, as well as inducing infringement of the '929 patent, and seeks monetary damages and injunctive relief.  

Last month, Celsis IVT successfully reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a similar patent infringement lawsuit involving the '929 patent.  Celsis is represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producing cryopreserved hepatocytes.  In general, this technology combines hepatocytes from multiple donors to create large lots with targeted activity levels, the result of which is a product that speeds up decision making and reduces the time and cost of drug research.  Since 2005, Celsis IVT has used this novel technology to create its unique LiverPool™ products for drug discovery research.  Major pharmaceutical companies around the world have incorporated these LiverPool products into their standard research protocols.  Research conducted with LiverPool has confirmed its outstanding efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies.  Additional LiverPool product information is available online at

"Celsis believes that innovations are the lifeblood of the life sciences industry.  Advancements must be protected and respected if we are to further the cause of cost-effective drug discovery," said Jay LeCoque, CEO of Celsis.  "We are extremely disappointed that we have been forced into this litigation, but the predatory pricing employed by Invitrogen and CellzDirect suggests a serious attempt to erode our patent-protected market position for the LiverPool product line."  He added, "These tactics are lowering, as well as undermining, the perceived value of new product innovations and inventions. We remain hopeful that the defendants will realize the serious impact of such a precedent on the entire life sciences industry, and that they will work with us to properly resolve this issue."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis Holdings, Inc., itself a subsidiary of Celsis International Ltd., is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development.  Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization.  Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research.  Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit

About Celsis International Ltd

Chicago-based Celsis International Ltd is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries.  Celsis divisions deliver substantial time and cost savings to customers while ensuring product quality and safety.  Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including the top 25 pharmaceutical companies worldwide. Details at

SOURCE Celsis In Vitro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis Receives Frost & Sullivan 2008 Best Practices Award
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
4. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
5. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
6. Chicago-Based Celsis International Goes Private
7. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
8. Celsis IVT Settles LiverPool Patent Infringement Suit With XenoTech, LLC
9. Celsis Rapid Detections Updated Drug Master Files (DMFs) Accepted by FDA
10. GBC Seeks Nominations for Regions Third Annual Bioscience Awards
11. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
Post Your Comments:
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP ... states to develop and pitch their BIG ideas to improve health and wellness in ... for votes to win the title of SAP's Teen Innovator, an all-expenses paid trip ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... BERLIN, Germany , October 27, 2015 ... 2015. SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically ... SMI,s Eye Tracking Glasses , so that ... Suite BeGaze. --> Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):